Banner About
Media Center
Press Release

Imperial College London Diabetes Centre Supports the Development of Diabetes Standard Set in Partnership with International Nonprofit

10 Mar 2019
Abu Dhabi

Imperial College London Diabetes Centre, part of Mubadala’s network of healthcare providers, has contributed to the definition of outcome measures that matter most to patients living with type 1 and type 2 diabetes, with the International Consortium for Health Outcomes Measurement (ICHOM). 

The Diabetes Standard Set, which was released following a year-long partnership with ICHOM, is a global standard set that defines health outcomes focused on the results that matter most to type-1 and type-2 diabetes patients. It serves as a data collection guide for physicians, who can incorporate it into each patient’s diabetes management plan to achieve value-based care that is centered on his or her needs. 

“We are very proud to be part of such an important initiative which contributes to the improvement of diabetes management both here in the UAE and around the globe, in line with Vision 2021,” said Dr. Safdar Naqvi, Medical Director and Consultant Physician & Endocrinologist at ICLDC. 

“At ICLDC we are at the forefront of developing a value-based approach that has the potential for positive change in clinical practices. The standard set will enable healthcare providers that measure it to pool our resources and expertise together for the best possible outcome. We will ultimately be able to learn from our results and each other’s, as well as improve the care we provide to our diabetes patients using evidence-based medicine, in a safe, effective manner and at a reasonable cost.”

Mona Khalid, Vice President, Outcomes Research & Development at ICHOM said: “We are pleased that Imperial College London Diabetes Centre has supported this important initiative. Their commitment, in providing expertise and funding to help establish these measures,  will bring consistency and transparency to the measurement of outcomes for people who live with type 1 and type 2 diabetes worldwide.The Diabetes  Set is the first step towards standardizing data collection internationally which will allow us to benchmark and identify opportunities to improve care for people living with the condition."
The outcomes defined, were determined by the 28 members of ICHOM Diabetes Working Group. Based in 19 countries and including medical experts, outcome researchers and patients, they discussed and voted on each outcome following a well-defined and structured process. The final list of outcomes was codified in the standard set and validated by 176 experts from 22 countries and 128 patients who live with diabetes from four countries.

The outcomes are a mix of clinical and Patient Reported Outcome Measures (PROMs) based on patients’ priorities. They include psychological wellbeing, diabetes distress, depression, glycemic control, diabetic ketoacidosis, and chronic complications, including those of the nervous and circulatory systems. Other outcomes were related to health services such as financial barriers to treatment and healthcare utilization. The standard set also includes defined instruments and time points for measurement for each outcome.

“The ultimate aim of this initiative is not only to drive value in healthcare but also improve the experience of each and every diabetes patient,” added Dr. Safdar Naqvi.

“This is a continuous exercise and the next step is for institutions around the world to join this project and start measuring and benchmarking the outcomes defined.”

Share This Article

Related Articles